Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy

Expert Opinion on Drug Safety · Published 2026-06-15 · DOI 10.1080/14740338.2026.2690266

Authors (1)

Terry J. Smith

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Smith, T. (2026). Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2026.2690266

Related articles

• Comparison of ciprofol and propofol on dreaming and emotional response during painless gastroscopy: a single-center randomized controlled trial · Expert Opinion on Drug Safety · 2025 · Same journal
• Rare irAEs associated with immune checkpoint inhibitor therapy · Expert Opinion on Drug Safety · 2026 · Same journal
• Safety and optimal use of direct oral anticoagulant therapy · Expert Opinion on Drug Safety · 2025 · Same journal
• Safe prescribing of antihypertensive drugs in the elderly and managing the risk of adverse events · Expert Opinion on Drug Safety · 2026 · Same journal
• Safety of anti-IL-5 compounds for the treatment of eosinophilic asthma with a focus on special populations · Expert Opinion on Drug Safety · 2026 · Same journal
• Long-term efficacy and safety of intra-articular corticosteroid injections in patients with knee osteoarthritis · Expert Opinion on Drug Safety · 2026 · Same journal
• Lessons from examining the safety of drugs for COVID-19 during pregnancy · Expert Opinion on Drug Safety · 2026 · Same journal
• COVID-19 vaccine safety studies- the need for a third group for extended monitoring · Expert Opinion on Drug Safety · 2025 · Same journal
• Safety and efficacy of hormonal therapies used to treat endometriosis in women suffering migraine · Expert Opinion on Drug Safety · 2026 · Same journal
• Dipyridamole-associated pulmonary edema: discovery of a new potential adverse reaction signal based on the FAERS database · Expert Opinion on Drug Safety · 2026 · Same journal